Scott Moomaw
Known title: SVP, CommercialCIK: 0001832592
Scott Moomaw's purchase track record
Scott Moomaw has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2022 | LQDA | $11K | -13.0% | +28.8% | -0.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LQDA | ▼ Sell | Open Market | 8,864 | $634K | 7/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 675 | $48K | 7/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 4,358 | — | 7/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,108 | — | 7/10/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 8,861 | $340K | 4/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,686 | $64K | 4/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,107 | — | 4/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 4,358 | — | 4/10/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,314 | $48K | 3/23/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 17,000 | $58K | 3/23/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 17,000 | $626K | 3/23/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 10,000 | $25K | 3/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 15,300 | $45K | 3/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 54,700 | $186K | 3/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 80,000 | $2.8M | 3/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 827 | $25K | 3/2/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 2/27/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 32,955 | $0 | 1/16/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 20,533 | $769K | 1/12/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,108 | — | 1/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 17,433 | — | 1/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 831 | $27K | 12/1/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 11/28/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 4,900 | $115K | 10/13/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,108 | — | 10/10/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 692 | $20K | 9/2/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 8,315 | $238K | 9/2/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 61,685 | $1.8M | 9/2/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 8/29/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 4,797 | $69K | 7/14/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,107 | — | 7/11/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 6,656 | $113K | 6/4/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 15,539 | — | 6/3/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 581 | $10K | 6/2/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 5/30/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 3,406 | $46K | 4/15/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 592 | $9K | 3/3/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 2/28/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 8,362 | $99K | 1/14/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 69,729 | $0 | 1/11/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 546 | $6K | 12/2/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 11/30/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,527 | $17K | 10/14/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 546 | $5K | 9/3/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 8/30/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,528 | $19K | 7/12/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 546 | $8K | 6/3/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 5/31/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,585 | $23K | 4/12/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 6,108 | $97K | 3/18/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 2/29/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 546 | $8K | 2/29/2024 | View on chart |
| LQDA | ▲ Buy | Grant | 49,723 | $0 | 1/11/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 11/30/2023 | View on chart |
| LQDA | ▼ Sell | Open Market | 542 | $4K | 11/30/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 8/31/2023 | View on chart |
| LQDA | ▼ Sell | Open Market | 537 | $4K | 8/31/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,875 | — | 5/31/2023 | View on chart |
| LQDA | ▼ Sell | Open Market | 651 | $5K | 5/31/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 7,500 | — | 2/28/2023 | View on chart |
| LQDA | ▼ Sell | Open Market | 2,171 | $16K | 2/28/2023 | View on chart |
| LQDA | ▲ Buy | Grant | 83,333 | $0 | 1/11/2023 | View on chart |
| LQDA | ▲ Buy | Open Market | 2,160 | $11K | 8/31/2022 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 7,650 | — | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.